Castle Biosciences
CSTL
181 hedge funds and large institutions have $1.51B invested in Castle Biosciences in 2021 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 78 increasing their positions, 45 reducing their positions, and 29 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 45
24% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 29
3% more funds holding
Funds holding: 175 → 181 (+6)
4% more capital invested
Capital invested by funds: $1.46B → $1.51B (+$53.1M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.38% less ownership
Funds ownership: 85.38% → 83.01% (-2.4%)
16% less call options, than puts
Call options by funds: $1.83M | Put options by funds: $2.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$32.3M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$29.4M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$29.4M |
| 4 |
BlackRock
New York
|
+$21.7M |
| 5 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$68.5M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$62.7M |
| 3 |
Select Equity Group
New York
|
-$24.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.1M |
| 5 |
Millennium Management
New York
|
-$17.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Walleye Capital
New York
| – | -$400 | -5,841 | Closed |
|
|
CAM
202
Cresset Asset Management
Chicago,
Illinois
| – | -$277K | -4,047 | Closed |
|
203
American Century Companies
Kansas City,
Missouri
| – | -$248K | -3,621 | Closed |
|
204
Tudor Investment Corp
Stamford,
Connecticut
| – | -$212K | -3,101 | Closed |
|
|
BC
205
Bridgefront Capital
Austin,
Texas
| – | -$205K | -2,994 | Closed |
|
|
DWA
206
Dorsey Wright & Associates
Pasadena,
California
| – | -$42.3K | -618 | Closed |
|
|
AS
207
Altshuler Shaham
Tel Aviv,
Israel
| – | -$38K | -558 | Closed |
|
|
CMBA
208
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$18K | -265 | Closed |
|
|
ACM
209
Allred Capital Management
Dallas,
Texas
| – | -$958 | -14 | Closed |
|
CSTL Hedge Fund Activity: Q2 2021 in Review
181 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q2 2021, worth a combined $1.51B — up 3.6% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CSTL positions and 29 closed out — a net gain of 7 holders — while 78 added to existing stakes and 45 trimmed.
The largest buyer was Macquarie Group, adding an estimated $32.3M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $68.5M sold.
- 181 institutional investors held Castle Biosciences (CSTL) as of Q2 2021, up from 175 in Q1 2021.
- Funds reported $1.51B of Castle Biosciences stock for Q2 2021, up 3.6% quarter-over-quarter.
- 36 funds opened new Castle Biosciences positions in Q2 2021 and 29 closed out, a net change of +7 holders.
- The largest Castle Biosciences buyer in Q2 2021 was Macquarie Group, an estimated $32.3M added.
- The largest Castle Biosciences seller in Q2 2021 was Matrix Capital Management Company, an estimated $68.5M sold.
Based on aggregated 13F filings for Q2 2021.